Conduit Pharmaceuticals INC

CDT Equity Inc. announced that a significant stockholder, Dr. Andrew Regan, has submitted a non-binding proposal to acquire all outstanding common stock at $2.00 per share, a 96.3% premium.

CDT Equity Inc. announced a 1-for-20 reverse stock split of its common stock, effective November 5, 2026, to comply with Nasdaq listing rules.

CDT Equity Inc. has entered into an evaluation agreement with Manoira Corporation to assess the potential of its clinical-stage assets AZD1656 and AZD5904 for enhancing Manoira's animal health products.

CDT Equity Inc. has entered into a material definitive agreement to issue a $6.75 million senior secured convertible note and warrants to J.J. Astor & Co., involving debt restructuring and potential equity dilution.

CDT Equity Inc. is implementing a 1-for-25 reverse stock split to comply with Nasdaq's bid-price rule, effective September 28, 2026.

CDT Equity Inc. has issued a $2.126 million convertible note and warrants to J.J. Astor & Co. as part of a financing arrangement.

CDT Equity Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing ongoing net losses, a substantial accumulated deficit, and significant concerns regarding its ability to continue as a going concern.

CDT Equity Inc. reported a net loss for Q1 2026, with significant strategic investments and ongoing liquidity concerns, while also detailing progress in R&D and partnerships.

CDT Equity Inc. reported a net loss of $7.1 million for Q3 2025 and $17.9 million for the nine months ended September 30, 2025, while advancing its data-driven biotech and digital asset treasury management strategy.

CDT Equity Inc. reported a wider net loss for the first half of 2025 despite significant capital raises, as it pivots to an AI-driven biotech development strategy and expands its asset portfolio.

CDT Equity Inc. restated its Q1 2025 financial results due to reclassification errors, reporting increased net losses and significant liquidity concerns, while actively pursuing strategic AI partnerships and asset development.

Conduit Pharmaceuticals reports a net loss of $5.1 million for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern.

CDT Equity Inc. files its annual report detailing its securities, corporate governance, financial metrics, and future outlook, highlighting ongoing development and strategic partnerships.

Conduit Pharmaceuticals details its securities, governance structure, and risk factors in its annual 10-K filing, highlighting its focus on clinical asset development and AI integration.

Conduit Pharmaceuticals outlines its capital structure, including common and preferred stock, and various warrants in its latest 10-K filing.

Andrew Regan and 1 other reported changes in beneficial ownership of Conduit Pharmaceuticals Inc. common stock on October 22, 2026.

Andrew Regan and 1 other reported changes in beneficial ownership of Conduit Pharmaceuticals Inc. common stock on July 30, 2026.

Andrew Regan, Chief Executive Officer and a Director of Conduit Pharmaceuticals Inc., sold 290 shares of common stock on July 30, 2026.

CDT Equity Inc. reports significant insider transactions including stock purchases and warrant exercises by CEO Andrew Regan and related entities.

Mark Taylor, a director and 10% owner of CDT Equity Inc., significantly increased his indirect beneficial ownership through the cashless exercise of pre-funded warrants.

CDT Equity Inc. acquired shares of Sarborg Limited from Director Chele Chiavacci Farley and other stockholders, issuing common stock and pre-funded warrants.

CDT Equity Inc. is holding a virtual special meeting on November 12, 2026, to seek stockholder approval for issuing shares related to convertible notes and warrants, and to approve amendments for a reverse stock split.

CDT Equity Inc. announced its 2026 virtual annual meeting of stockholders, detailing proposals including director elections, auditor ratification, reverse stock splits, and share issuances.

CDT Equity Inc. is seeking stockholder approval for several critical proposals, including significant share issuances, an equity line of credit, a reverse stock split, an increase in authorized shares, and redomestication to the Cayman Islands.

Conduit Pharmaceuticals Inc. announced its 2025 virtual annual meeting to elect directors, ratify auditors, and approve a significant increase in its stock incentive plan, while detailing recent management changes, related party transactions, and a new licensing agreement with AstraZeneca.

Conduit Pharmaceuticals is asking stockholders to approve a reverse stock split, ranging from 1-for-2 to 1-for-100 (and up to 1-for-250 in aggregate), to potentially maintain its Nasdaq listing and attract investors.

Conduit Pharmaceuticals is holding a special virtual meeting on January 9, 2025, to seek stockholder approval for the issuance of common stock related to warrant exercises and the conversion of promissory notes.

CDT Equity Inc. has filed an S-1 registration statement to allow selling stockholders to resell up to 16,825,644 shares of common stock, detailing ongoing financial challenges and strategic initiatives.

Conduit Pharmaceuticals enters into a licensing agreement with AstraZeneca, gaining exclusive rights to develop and commercialize certain pharmaceutical compounds in exchange for upfront payments, equity issuance, and future revenue sharing.

Conduit Pharmaceuticals files an S-1 registration statement for the resale of up to 22,004,465 shares of common stock issued to AstraZeneca and Nirland Limited.

Corvus Capital, a major shareholder, has proposed acquiring all outstanding shares of CDT Equity Inc. not already owned by the reporting persons at $2.00 per share, a significant premium to the current market price.

An amendment to a Schedule 13D filing reveals updated beneficial ownership details for CDT Equity Inc. by Corvus Capital Ltd., Manoira Corporation, and Andrew Regan.

Corvus Capital Ltd. and Andrew Regan have increased their beneficial ownership in CDT Equity Inc. to 43.7% following the exercise of pre-funded warrants.

Corvus Capital Ltd. and Andrew Regan have amended their Schedule 13D filing for CDT Equity Inc., reporting increased beneficial ownership to 5.3% and 5.4% respectively, following warrant exercises and open market purchases.

Mark Taylor and his entities, Prospect Capital and Prospect Finance, significantly increase their stake in CDT Equity Inc. to 43.79% following a strategic acquisition and warrant exercise.

Corvus Capital Ltd. increased its beneficial ownership in CDT Equity Inc. to 12.2% by acquiring a subsidiary and receiving shares and pre-funded warrants as part of a $7 million settlement.

Ascent Partners Fund LLC and affiliated entities have reported a beneficial ownership of 9.9% in CDT Equity Inc. common stock, subject to a 9.99% ownership cap.

Several entities have filed an amendment to their Schedule 13G, reporting beneficial ownership of CDT Equity Inc. common stock has fallen below the 5% threshold.

Multiple entities report a combined 9.2% beneficial ownership of CDT Equity Inc. common stock following a reverse stock split.

Mark Taylor, Prospect Capital, and Prospect Finance have filed an amendment to Schedule 13G, indicating they no longer hold over 5% beneficial ownership of CDT Equity Inc. common stock following a reverse stock split.

Craig Wigglesworth has filed an amendment to his Schedule 13G, reporting a beneficial ownership of 3.4% in CDT Equity Inc. after a reverse stock split, marking an exit from his previous significant stake.

Craig Wigglesworth has filed a Schedule 13G, disclosing beneficial ownership of 1,258,042 shares, representing 9.6% of CDT Equity Inc.'s outstanding common stock.